2005 Food and Drug Administration Networking Side effects 
European Pharmaceutical Review
SEPTEMBER 22, 2023
Limitations of monoclonal antibody therapies Regulatory approvals from the US Food and Drug Administration (FDA) for aducanumab and lecanemab – and likely very soon for donanemab also – opened a route for different therapeutic modalities and other relevant disease targets, such as tau.
Pharma Marketing Network
JUNE 11, 2020
You know, in November 2009, the FDA held a public hearing about the promotion of Food and Drug Administrative Related Regulated Medical Products, using the internet and social media tools. They would write up the presentations by physicians about drugs. So that was 2005. So, I didn’t look so bad. It’s a blog.
Expert insights. Personalized for you.
76 
Let's personalize your content